LBT Innovations Ltd
ASX:LBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (13.8), the stock would be worth AU$-0.03 (269% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.1 | AU$0.02 |
0%
|
| Industry Average | 13.8 | AU$-0.03 |
-269%
|
| Country Average | 13.2 | AU$-0.03 |
-262%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
LBT Innovations Ltd
ASX:LBT
|
29.9m AUD | -8.1 | -8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 55.2 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 16.8 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 24.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 14.6 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 19.6 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 30.4 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 13.1 | 18.9 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 38.8 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 12.6 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 16.9 | 21.8 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
LBT Innovations Ltd
Glance View
LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia. The company went IPO on 2006-07-31. The firm is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets. The firm's product pipeline includes The Automated Plate Assessment System for antimicrobial resistance (APAS-AMR), WoundVue, Biofilm, Automated Gram Stain Assessment and MicroStreak. The firm's Automated Plate Assessment System (APAS) Independence is a platform technology that automates culture-plate screening and interpretation. APAS Independence screens, interprets, and sorts these plates, overcoming the bottleneck in lab workflows and freeing up microbiologist's time. Its APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates.
